About Tissue Heart Valves
Heart valves are prosthetic cardiovascular medical devices that are used to replace a defective heart valve. These valves can be biological (tissue) or mechanical. Manufacturers develop tissue heart valves from various sources such as bovine, porcine, and human tissues. Devices developed using human tissues are known as allografts or homografts. The implantation of these devices does not require the lifelong use of blood-thinner medications compared to mechanical tissue heart valves. They also ensure unidirectional flow of the blood across heart chambers. The medical facilities worldwide perform about 300,000 heart valve replacement procedures each year.
Technavio’s analysts forecast the global tissue heart valves market to grow at a CAGR of 3.81% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global tissue heart valves market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of tissue heart valve implants.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Tissue Heart Valves Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Tissue Heart Valves Market: Edwards Lifesciences, LivaNova, Medtronic and St. Jude Medical
Other Prominent Vendors in the market are: Braile Biomédica, CryoLife and Labcor Laboratórios
Commenting on the report, an analyst from Technavio’s team said: “Vendors undergo M&A to extend their product offerings, increase their market shares, and expand their operations. They acquire other companies to enhance their R&D capabilities for manufacturing innovative devices that meet consumer needs. Acquisition of other companies allows vendors access to the product portfolio of the acquired company. M&A as a business strategy helps new players enter the market.”
According to the report, demand for stentless tissue valves is driving the market growth during the forecast period. Physicians prefer stentless tissue valves as they have a wider valve opening. This allows the blood to flow more freely similar to a normal, healthy valve. The tissue stentless tissue heart valves are flexible. This flexibility along with a wider valve opening helps the blood to avoid a damaged stent in the heart and flow uniformly.
Further, the report states that Lack of skilled personnel is hindering the market growth. The number of interventional cardiologists in medical facilities, such as hospitals and clinics worldwide, is low. Moreover, the technical expertise of medical professionals in local medical facilities is not up to par with those in well-known facilities.
Edwards Lifesciences, LivaNova, Medtronic, St. Jude Medical, Braile Biomédica, CryoLife, Labcor Laboratórios
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook